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Background: Familial Colorectal Cancer Type X (FCCTX) is defined as individuals with colorectal cancer (CRC) who families meet
Amsterdam Criteria-1 (AC1), but whose tumours are DNA-mismatch-repair-proficient, unlike Lynch syndrome (LS). FCCTX does
not have an increased risk of extra-colonic cancers. This analysis compares epidemiologic and clinicopathologic features among
FCCTX, LS, and ‘non-familial’ (non-AC1) CRC cases.
Methods: From the Colon Cancer Family Registry, FCCTX (n¼ 173), LS (n¼ 303), and non-AC1 (n¼ 9603) CRC cases were
identified. Questionnaire-based epidemiologic information and CRC pathologic features were compared across case groups
using polytomous logistic regression.
Results: Compared with LS, FCCTX cases were less likely to be current (vs never) smokers; have a proximal subsite (vs rectal)
tumour; or have mucinous histology, poor differentiation, or tumour-infiltrating lymphocytes. There were no observed differences
in co-morbidities or medication usage.
Conclusions: FCCTX were less likely to be current tobacco users; other exposures were similar between these groups.
Histopathologic differences highly suggestive of LS CRCs do not appear to be shared by FCCTX.
‘Familial Colorectal Cancer Type X’ (FCCTX) collectively describes
cases of colorectal cancer (CRC) that meet clinical Amsterdam
Criteria-1 (AC1) for Lynch syndrome (LS), but whose tumours are
DNA-mismatch-repair-proficient as assessed by tumour immuno-
histochemistry (IHC) and/or microsatellite instability (MSI) testing
(Vasen et al, 1991; Lindor et al, 2005). Approximately half of CRC
cases who meet AC1 (three relatives with CRC across two
successive generations (with one case being a first-degree relative
of the other two), at least one case diagnosed before age 50, and the
exclusion of familial adenomatous polyposis), are now classified as
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FCCTX (Lynch & de la Chapelle, 2003; Renkonen et al, 2003;
Schiemann et al, 2004; Woods et al, 2005). FCCTX pedigrees show
an autosomal-dominant inheritance pattern, but the genetic basis
remains unknown, and may constitute more than one genetic
aetiology.
Previous studies have indicated clinical and pathologic
differences between FCCTX and LS (online Supplementary
Table S1). Relative to LS, FCCTX is associated with lower
predisposition to CRC (standard incidence ratio 2.3 vs 6.1), is not
associated with extracolonic cancers (Lindor et al, 2005), has an
older mean age at diagnosis (50–60 years vs 40 years), is more
likely to be left-sided, and is less likely to be associated with
synchronous or metachronous cancers. Histopathologically,
FCCTX vs LS CRCs have more heterogeneous architecture, a
predominant tubular growth pattern, less frequent mucinous
histology, and less often with peritumoural or tumour-infiltrating
lymphocytes (TIL) (Schiemann et al, 2004; Lindor et al, 2005;
Llor et al, 2005; Mueller–Koch et al, 2005; Dove-Edwin et al,
2006; Valle et al, 2007; Chen et al, 2008; Koh et al, 2011; Klarskov
et al, 2012).
To our knowledge, there have been no reports that compare
epidemiologic characteristics across FCCTX, LS, and non-Amster-
dam Criteria-1 (non-AC1) cases and there are few large studies
that describe the breadth of histopathologic features in these
groups. Our study aimed to describe the demographic, environ-
mental, and tumour characteristics of FCCTX and determine how
they compare with LS and non-AC1 cases within the Colon Cancer
Family Registry (CCFR).
MATERIALS AND METHODS
As described elsewhere (Newcomb et al, 2007), the CCFR (http://
coloncfr.org) is an international consortium of CRC cases and
controls from population- and/or clinic-based sites in North
America and Australasia. Recruited during 1998–2007, participants
completed written informed consent for study enrolment; proto-
cols were approved by local institutional review boards. Collection
of epidemiologic and family history data and biospecimens was
standardised across all centres.
The following tumour characteristics were abstracted from the
clinical histopathology report and/or from pathologist review: location,
size, nodal status, differentiation, histologic type, and presence/absence
of peritumoural lymphocytes, Crohn’s-like reaction, tumour-infiltrat-
ing lymphocytes, and venous invasion. MSI and/or IHC were perfor-
med on all tumour samples (Lindor et al, 2005; Newcomb et al, 2007).
Cases were allocated to one of the three groups: (1) ‘LS’
(n¼ 312) for cases meeting AC1 and whose tumours were
classified as MSI (MSI-high and/or MMR-deficient), (2) ‘FCCTX’
(n¼ 177) for cases meeting AC1, but with non-MSI tumours, or
(3) ‘non-AC1’ (n¼ 12,175) for the remainder of CRC cases whose
family histories did not meet AC1. No more than one individual
per family was included in the analysis. Restricting the analysis to
available epidemiologic/tumour information, we included 173/146
FCCTX, 303/245 LS, and 9603/7878 non-AC1 CRC cases.
Statistical methods. Odds ratios (OR) with 95% confidence
intervals were estimated using polytomous logistic regression
Table 1. Epidemiologic characteristics of FCCTX compared with Lynch syndrome and non-Amsterdam Criteria-1 colorectal cases in the Colon Cancer
Family Registry
Characteristic, n (%)
FCCTX
(n¼173)
Lynch
(n¼303)
Non-AC1
(n¼9,603)
FCCTX vs Lyncha
ORb (95% CI)
FCCTX vs
non-AC1a
ORb (95% CI)
Lynch vs non-AC1a
ORb (95% CI)
Case characteristicsc
Age, mean (s.d.) 53.3 (11.3) 50.5 (11.4) 56.3 (12.0) 1.02 (1.00, 1.03) 0.99 (0.98, 1.00) 0.97 (0.96, 0.98)
Male gender 76 (44%) 149 (49%) 4797 (50%) 0.81 (0.56, 1.18) 0.80 (0.59, 1.09) 0.99 (0.79, 1.25)
BMI, mean (s.d.) 27.5 (6.6) 26.5 (5.8) 27.2 (5.8) 1.03 (0.10, 1.07) 1.02 (0.99, 1.04) 0.98 (0.96, 1.01)
Smoking
Never 85 (49%) 148 (49%) 4252 (45%) 1 (Reference) 1 (Reference) 1 (Reference)
Former 74 (43%) 106 (35%) 4198 (44%) 1.17 (0.78, 1.76) 0.99 (0.72, 1.37) 0.85 (0.65, 1.11)
Current 13 (8%) 49 (16%) 1096 (11%) 0.48 (0.24, 0.94) 0.62 (0.35, 1.13) 1.30 (0.93, 1.83)
Co-morbidities (yes/no) (% yes)
Diabetes 17/155 (9%) 20/283 (7%) 1154/8404 (12%) 1.48 (0.74, 2.94) 1.16 (0.69, 1.94) 0.78 (0.49, 1.25)
Hyperlipidemia 42/129 (24%) 79/222 (26%) 2995/6530 (31%) 0.84 (0.53, 1.31) 0.88 (0.61, 1.27) 1.05 (0.80, 1.39)
Aspirin 38/134 (22%) 68/231 (22%) 2771/6747 (29%) 0.83 (0.52, 1.34) 0.99 (0.68, 1.46) 1.19 (0.89, 1.60)
Acetaminophen 23/149 (13%) 51/250 (17%) 1469/8026 (15%) 0.72 (0.42, 1.23) 0.81 (0.52, 1.27) 1.13 (0.83, 1.55)
NSAIDs 31/141 (18%) 53/249 (17%) 1555/7910 (16%) 1.01 (0.62, 1.66) 1.16 (0.78, 1.73) 1.14 (0.84, 1.56)
Laxatives 39/133 (23%) 60/242 (20%) 2136/7375 (22%) 1.04 (0.65, 1.65) 1.04 (0.72, 1.51) 1.01 (0.75, 1.36)
Multivitamin 73/99 (42%) 131/171 (43%) 4829/4702 (50%) 0.88 (0.60, 1.31) 0.98 (0.71, 1.34) 1.10 (0.86, 1.41)
Folic acid 22/150 (13%) 39/261 (13%) 941/8528 (10%) 1.03 (0.58, 1.84) 1.13 (0.70, 1.80) 1.09 (0.76, 1.57)
Calcium 36/136 (21%) 59/244 (19%) 2507/7012 (26%) 0.84 (0.51, 1.38) 0.80 (0.54, 1.19) 0.95 (0.70, 1.30)
Female (yes/no) (% yes)
Oral hormonal contraceptives 70/27 (72%) 115/39 (75%) 2783/1972 (58%) 0.93 (0.50, 1.72) 1.31 (0.81, 2.12) 1.41 (0.95, 2.09)
PMH with uterus intact 23/41 (36%) 48/67 (41%) 1041/1805 (36%) 0.44 (0.05, 3.92) 0.90 (0.12, 6.80) 2.04 (0.76, 5.42)
PMH with hysterectomy 6/12 (33%) 12/26 (32%) 314/471 (39%) 0.68 (0.35, 1.34) 1.19 (0.68, 2.09) 1.76 (1.17, 2.64)
Abbreviations: AC1¼Amsterdam Criteria-1; BMI¼body mass index; FCCTX¼Familial Colorectal Cancer Type X; PMH¼post-menopausal hormone use; s.d.¼ standard deviation.
aAll models are adjusted for age at diagnosis, sex, and study site.
bOR per one unit increase in continuous variables (age at diagnosis and BMI). For binary variables, the reference group is those without the characteristic.
cAge¼ age at diagnosis (years); BMI¼BMI two years prior to diagnosis (kg m 2).
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comparing case groups: FCCTX vs LS, FCCTX vs non-AC1, and LS
vs non-AC1. ORs were adjusted for age at diagnosis, sex, and study
site. Smoking history (ever/never smoked Z1 cigarette a day for
Z3 months) was based on the history 1 year preceding diagnosis.
Age at diagnosis and pre-diagnostic body mass index (BMI) were
included in models as continuous variables. All other covariates
were binary. Complete-cases analyses were conducted for all
variables, with the exception of the histopathologic variables, which
include those with missing and unknown as a separate category.
Duplicates were removed for the limited number of participants
(n¼ 307; 3.6%) who contributed more than one tumour sample.
Analyses were performed using SAS 9.3 (Cary, NC, USA) and R
3.0.0 (Vienna, Austria). Reported P-values are two-sided; Pr0.05
was considered statistically significant.
RESULTS
FCCTX cases were slightly older at diagnosis than LS (mean 53.3 vs
50.5 years Table 1). By definition, all FCCTX and LS families met
AC-1. In comparison, of the 9603 individuals who were classified
as non-AC1, 33% were diagnosed before age 50, 5% had two or
more first-degree relatives with CRC (13% had one first-degree
relative), and 15% had MSI-high tumours.
The self-reported proportion of ever smokers was similar across
the three groups, but FCCTX had the lowest prevalence of current
smokers (P¼ 0.03 and 0.12 compared with LS and non-AC1,
respectively). A higher proportion of FCCTX vs LS reported being
former smokers. BMI and the prevalence of diabetes, hyperlipide-
mia, aspirin/NSAID and other medication usage, and gynaecologic
history elements did not vary significantly between groups.
FCCTX CRCs were less often located in proximal subsites than
LS (caecal, ascending, or transverse colon; all Po0.001, Table 2);
no subsite difference was observed for FCCTX vs non-AC1
tumours. Overall, the LS group had the lowest proportion of T4
tumours, but a statistically significant difference was observed only
when comparing LS and non-AC1 CRCs. Nodal N-stage could not
be reliably assessed owing to the variability in missing data between
sites (data not shown).
FCCTX CRCs were more commonly poorly differentiated
compared with LS/non-AC1 tumours, and were less often
mucinous than LS tumours. FCCTX tumours had a smaller
proportion of peritumoural lymphocytes, Crohn’s-like reaction,
Table 2. Histopathologic characteristics of FCCTX in CCFR compared with Lynch syndrome and non-Amsterdam Criteria-1 colorectal cases
Characteristic,
n (%)
FCCTX
(n¼146)
Lynch
(n¼245)
Non-AC1
(n¼7,878)
FCCTX vs Lyncha
OR (95% CI)
FCCTX vs non-
AC1a
OR (95% CI)
Lynch vs non-AC1a
OR (95% CI)
Cancer subsite
Caecum 17 (12%) 55 (22%) 1034 (13%) 0.18 (0.09, 0.37) 0.95 (0.54, 1.67) 5.2 (3.32, 8.14)
Ascending 15 (10%) 64 (26%) 1129 (14%) 0.13 (0.06, 0.27) 0.66 (0.35, 1.22) 5.22 (3.37, 8.07)
Transverse 13 (9%) 31 (13%) 578 (7%) 0.27 (0.12, 0.59) 1.18 (0.63, 2.21) 4.44 (2.67, 7.41)
Descending 7 (5%) 14 (6%) 438 (6%) 0.38 (0.14, 1.08) 0.78 (0.35, 1.74) 2.03 (1.03, 3.99)
Sigmoid 37 (25%) 22 (9%) 1931 (25%) 1.02 (0.51, 2.04) 0.98 (0.63, 1.52) 0.96 (0.55, 1.66)
Rectum 50 (34%) 37 (15%) 2455 (31%) 1 (Reference) 1 (Reference) 1 (Reference)
Missing/other 7 (5%) 22 (9%) 313 (4%)
T-stage
T1 22 (15%) 27 (11%) 958 (12%) 1 (Reference) 1 (Reference) 1 (Reference)
T2 26 (18%) 48 (20%) 1328 (17%) 0.75 (0.35, 1.57) 0.78 (0.43, 1.40) 1.04 (0.64, 1.70)
T3 74 (51%) 127 (52%) 4242 (54%) 0.85 (0.45, 1.63) 0.65 (0.39, 1.07) 0.76 (0.49, 1.18)
T4 11 (8%) 9 (4%) 576 (7%) 1.75 (0.60, 5.05) 0.72 (0.34, 1.52) 0.41 (0.19, 0.89)
Missing 13 (8%) 34 (13%) 774 (10%)
Differentiation
Well 22 (15%) 21 (9%) 633 (8%) 1 (Reference) 1 (Reference) 1 (Reference)
Moderate 97 (66%) 127 (52%) 4712 (60%) 0.88 (0.45, 1.75) 0.62 (0.38, 1.02) 0.70 (0.43, 1.15)
Poor 16 (11%) 55 (22%) 1149 (15%) 0.33 (0.14, 0.78) 0.41 (0.21, 0.82) 1.25 (0.73, 2.14)
Missing/other 11 (8%) 42 (17%) 1384 (18%)
Histology
Adenocarcinoma 132 (90%) 191 (78%) 6771 (86%) 1 (Reference) 1 (Reference) 1 (Reference)
Mucinous 11 (8%) 41 (17%) 856 (11%) 0.39 (0.19, 0.80) 0.68 (0.36, 1.27) 1.72 (1.21, 2.45)
Signet ring 1 (1%) 4 (2%) 79 (1%) 0.38 (0.04, 3.44) 0.68 (0.09, 4.96) 1.79 (0.64, 5.07)
Missing/other 2 (1%) 9 (4%) 172 (2%)
Additional features (yes/no) (% yes)b
Peritumoural lymphocytes 23/57 (28%) 61/71 (46%) 954/1608 (37%) 0.49 (0.26, 0.90) 0.75 (0.45, 1.25) 1.54 (1.07, 2.23)
Crohn’s-like lymphocytes 14/60 (19%) 61/70 (37%) 627/1843 (25%) 0.27 (0.14, 0.54) 0.78 (0.43, 1.41) 2.84 (1.97, 4.10)
Tumour-infiltrating
lymphocytes
20/65 (24%) 98/43 (70%) 704/1920 (27%) 0.14 (0.07, 0.26) 0.89 (0.53, 1.50) 6.41 (4.40, 9.36)
Venous invasion 16/79 (11%) 9/135 (4%) 735/4027 (9%) 3.21 (1.35, 7.65) 1.27 (0.73, 2.21) 0.40 (0.20, 0.79)
Abbreviations: AC1¼Amsterdam Criteria-1; FCCTX¼Familial Colorectal Cancer Type X.
aAll models are adjusted for age at diagnosis, sex, and study site. Reference group is those without the characteristic.
bThese features were only collected at four of six study sites (Mayo Clinic, Australasia, UH, and CCO).
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and TIL than LS CRCs, but there was no difference compared with
non-AC1 tumours. Venous invasion was most commonly seen in
FCCTX tumours.
DISCUSSION
This study evaluated epidemiologic and clinicopathologic data
across FCCTX, LS, and non-AC1 cases of CRC. A statistically
significant difference across these groups was noted for smoking
history, whereas no differences were observed in co-morbidities,
medication use, or gynaecologic history elements. Classic histo-
pathologic features of LS CRCs were much less commonly
observed in FCCTX CRCs. There were no clear distinguishing
features for FCCTX vs non-AC1 tumours.
Comparison of FCCTX and LS. Individuals classified as FCCTX
were less likely to be current smokers. Tobacco use is associated
with a higher incidence of colorectal adenoma and invasive CRC in
both the general population and in LS (Watson et al, 2004; Botteri
et al, 2008; Pande et al, 2010). The difference in CRC prevalence
between FCCTX and LS may be partially mediated by differences
in tobacco use habits, although we cannot rule out that smoking
has less effect in FCCTX than in LS.
In this comprehensive pathologic analysis, we confirmed the
previously-reported left- vs right-sided predominance of FCCTX vs
LS by subsite (Llor et al, 2005; Mueller-Koch et al, 2005; Valle et al,
2007). In the present analysis, there were also a greater proportion
of large (T4) primary FCCTX tumours compared with LS CRCs.
On histologic review, the mucinous histology, poor differentiation,
and TIL features reported as characteristic of LS tumours (Jenkins
et al, 2007) were not common in FCCTX CRCs. Prior studies have
analysed some of these features, but with inconsistent results (Llor
et al, 2005; Valle et al, 2007; Chen et al, 2008; Klarskov et al, 2011;
Koh et al, 2011; Klarskov et al, 2012). FCCTX CRCs in our analysis
also had a lower proportion for peritumoural lymphocytes and
Crohn’s-like reaction, but a significantly higher proportion had
venous invasion relative to that observed in LS CRCs.
Comparison of FCCTX and non-AC1. Epidemiologic factors did
not distinguish FCCTX and non-AC1 cases. FCCTX tumours had
significantly lower frequency of poor differentiation than non-AC1
CRCs and a trend toward a higher proportion with venous invasion.
Tumour subsite, T-stage, and tumoural lymphocytes were not
observed to differ between FCCTX and non-AC1 tumours.
Strengths and limitations. This analysis benefits from a large,
international cohort of patients with standardised data collection,
providing the opportunity to compare FCCTX, LS, and non-AC1
CRCs in the first epidemiologic and in-depth clinicopathologic
analysis. The epidemiologic features were assessed by a single
baseline survey, as it is difficult to longitudinally evaluate any
changes in these factors in such rare syndromes. To keep this
analysis meaningful, we selected a classification based on the
current information readily available to clinicians, namely personal
and family history (the Amsterdam Criteria) and standard tumour
analysis (MSI and/or MMR IHC). The non-AC1 cohort contains a
mixture of sporadic MSI (typically due to MLH1 promoter
hypermethylation and associated sporadic BRAF mutations
(Lynch et al, 2007)) and non-MSI cases. CRC is increasingly being
recognised as genetically and epigenetically heterogeneous (Marisa
et al, 2013), making selection of a true comparison group difficult.
FCCTX is likely also genetically heterogeneous and would benefit
from in-depth molecular characterisation (Abdel-Rahman et al,
2005; Sanchez-de-Abajo et al, 2007; Goel et al, 2010). It should also
be noted that it is possible, given the multiple statistical
comparisons performed in this analysis, that the noted associations
could be chance findings. Thus, independent validation is needed.
CONCLUSIONS
This study compared FCCTX, LS, and non-AC1 CRC cases.
FCCTX were less likely to be current tobacco users; other
exposures were similar between these groups. Subsite analysis
confirms the distal colonic predominance of FCCTX vs LS CRCs.
Histopathologically, mucinous histology, poor differentiation, and
TIL were strongly associated with LS, rather than FCCTX or non-
AC1, tumours, whereas venous invasion was more commonly seen
in FCCTX. Additional molecular analysis may eventually explain
the observed histopathologic differences between FCCTX and LS
tumours.
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